Welcome to our dedicated page for Accolade news (Ticker: ACCD), a resource for investors and traders seeking the latest updates and insights on Accolade stock.
Accolade, Inc. (ACCD) delivers technology-powered healthcare solutions that combine virtual care with expert clinical navigation. This news hub provides investors and industry professionals with essential updates on the company’s strategic initiatives and market position.
Track official press releases, earnings announcements, and operational developments through our curated collection. Find timely information on healthcare partnerships, service expansions, and technology innovations that shape Accolade’s role in personalized care solutions.
Our repository includes updates across key business areas: financial results, leadership changes, clinical program enhancements, and regulatory milestones. Each entry is sourced directly from company communications to ensure accuracy and compliance.
Bookmark this page for streamlined access to ACCD’s evolving story in healthcare technology. Monitor how the company’s unique blend of digital tools and clinical expertise continues to redefine employer-sponsored and individual healthcare navigation.
Transcarent has successfully completed its merger with Accolade, creating a comprehensive health and care platform serving over 20 million members and 1,700 employer and health plan clients. The transaction, valued at approximately $621 million, involved Accolade shareholders receiving $7.03 per share in cash.
The combined organization integrates Transcarent's AI-powered WayFinding and comprehensive Care Experiences with Accolade's expertise in health advocacy, expert medical opinion, and virtual primary care. The merger brings together their technological capabilities, including generative AI solutions and data-driven platforms, to deliver personalized healthcare services.
Under the leadership of CEO Glen Tullman and newly promoted President Snezana Mahon, the company aims to provide enhanced healthcare access through their Experience Store, offering various point solutions and care experiences on a single secure platform. Following the acquisition, Accolade has been delisted from Nasdaq and is now part of a privately held company.
Accolade (NASDAQ:ACCD) stockholders have approved the merger with Transcarent during a special meeting held on March 27, 2025. The transaction is expected to complete in Q2 2025, subject to customary closing conditions and state regulatory approvals. Upon completion, Accolade will become a private company, delisting its shares from public markets.
Evercore is serving as Transcarent's exclusive financial advisor with Wilson Sonsini Goodrich & Rosati as legal advisor. Morgan Stanley & Co and Cooley LLP are acting as Accolade's financial and legal advisors respectively.
Accolade is a Personalized Healthcare company providing virtual primary care, mental health services, and care navigation, maintaining over 90% consumer satisfaction ratings. Transcarent offers Care Experiences and AI-powered WayFinding for benefits navigation and care delivery.
Accolade (Nasdaq: ACCD) has announced a strategic partnership with Oshi Health, a virtual GI clinic, expanding its digestive health solutions alongside existing partner Cylinder. The collaboration aims to address the significant healthcare challenge of GI diseases, which affect 70 million Americans annually and generate $136 billion in healthcare costs.
The partnership tackles critical issues in GI care, including lengthy diagnosis waiting times (2-3 years on average) and access to comprehensive treatment. Oshi Health provides integrated care through virtual consultations with GI specialists, dietitians, and psychologists, achieving 92% symptom control rate within 10 weeks.
This initiative specifically targets digestive health conditions, which represent the second leading cause of workplace absences. Oshi Health's services are in-network with major insurance plans, and the partnership includes purpose-built integrations to improve access to specialized GI care for Accolade's customer base.
Transcarent and Accolade (NASDAQ:ACCD) announced the expiration of the Hart-Scott-Rodino waiting period for their pending merger, marking a significant milestone toward completing their transaction. The merger is expected to close in Q2 2025, subject to Accolade stockholder approval and other customary conditions.
The combination aims to integrate Transcarent's AI-powered WayFinding solution and comprehensive care experiences with Accolade's advocacy, expert medical opinions, and primary care services. The merger will create a platform focused on improving healthcare access and decision-making for consumers.
Evercore serves as Transcarent's financial advisor, while Morgan Stanley & Co advises Accolade. The deal brings together two companies focused on delivering high-quality, affordable healthcare solutions through a combination of technology and human support.
Transcarent has announced its acquisition of Accolade (NASDAQ:ACCD) for $7.03 per share in cash, representing a total equity value of approximately $621M. The deal, unanimously approved by both companies' boards, represents a 110% premium over Accolade's closing price on January 7, 2025.
The combined platform will integrate Transcarent's generative AI-powered WayFinding and comprehensive care experiences with Accolade's Personalized Healthcare Platform, advocacy, expert medical opinions, and primary care services. The merger will create an industry-leading platform serving over 1,400 employer and payer clients.
The transaction is expected to close during the second quarter of 2025, subject to Accolade stockholder approval and regulatory approvals. Upon completion, Accolade will become private and delist from Nasdaq. The company expects to report Q3 fiscal 2025 results within previously provided guidance but has withdrawn future financial guidance due to the acquisition.
Accolade (NASDAQ: ACCD) announced that its virtual healthcare service PlushCare now accepts Medicare Part B coverage, extending access to 64 million beneficiaries across all 50 states. The expansion provides primary care, clinical weight management, and mental health support services to older adults and individuals with disabilities or chronic conditions.
The initiative addresses significant healthcare barriers, particularly relevant as approximately 5.8 million Americans face difficulties accessing medical care, and 21% of adults aged 65+ experience mobility disabilities. PlushCare's platform enables diagnosis and treatment of over 6,800 medical conditions, allowing patients to choose their preferred healthcare providers while receiving care from home.
This expansion aligns with recent legislative developments that extended Medicare telehealth waivers until March 31, 2025, emphasizing virtual care's role in healthcare accessibility.
Transcarent has announced the acquisition of Accolade (NASDAQ:ACCD) for $7.03 per share in cash, representing a total equity value of approximately $621M. The deal offers a 110% premium over Accolade's closing price on January 7, 2025.
The combined platform will integrate Transcarent's generative AI-powered WayFinding and comprehensive care experiences with Accolade's Personalized Healthcare Platform, advocacy, expert medical opinions, and primary care services. The merger will serve more than 1,400 employer and payer clients.
The transaction, unanimously approved by both companies' Boards of Directors, is expected to close during the second calendar quarter of 2025, subject to Accolade stockholder approval and regulatory approvals. The deal will be financed through equity funding led by General Catalyst and Glen Tullman's 62 Ventures. Upon completion, Accolade will become private and delist from Nasdaq.
Accolade (NASDAQ: ACCD) has announced it will release its fiscal third quarter 2025 financial results on Thursday, January 9, 2024 after market close. The company will host a conference call to discuss the results at 4:30 p.m. E.T. on the same day. Pre-registration is required for telephone access, and participants will receive dial-in details upon registration. The call will also be accessible via live audio webcast on the company's investor relations website. A replay will be available for one year on the same platform.
Accolade (NASDAQ: ACCD) has announced its participation in three upcoming investor conferences. The company will present at the Stephens Annual Investment Conference in Nashville on November 20 at 9:00 am CT, attend the CG MedTech, Diagnostics and Digital Health & Services Forum in New York on November 21 (for one-on-one meetings only), and present at the Piper Sandler 36th Annual Healthcare Conference in New York on December 5 at 10:00 am ET. Webcasts will be available at ir.accolade.com with replays accessible for 90 days, except for the CG MedTech event which will not be webcast.
Accolade, Inc. (Nasdaq: ACCD) has announced a partnership with Renalogic, a leader in managing chronic kidney disease (CKD) costs for self-insured employers. Renalogic will join Accolade's Trusted Partner Ecosystem, offering CKD risk management and dialysis cost containment solutions. This partnership aims to address the rising health costs for employers, particularly the high expenses associated with late-stage CKD and dialysis.
Renalogic's services include:
- ImpactIQ: Data algorithms to identify diagnosed and undiagnosed CKD members
- ImpactAdvocate: Support to delay end-stage renal disease and manage dialysis starts
- ImpactProtect: Advising on fair market rates for dialysis services
The partnership is expected to drive cost savings for customers while improving health outcomes for CKD members. Accolade and Renalogic will provide integrations to joint customers at no additional cost, including warm handoffs from Accolade Care Advocates to Renalogic's clinical team.
